To hear about similar clinical trials, please enter your email below
Trial Title:
Evaluation of the Use of Minced Skin Grafts for Promoting Donor Site Wound Healing After Split-Thickness Skin Grafting
NCT ID:
NCT06488612
Condition:
Traumatic Skin Loss, 2nd and 3rd Degree Burn, Post Tumour Excision - Raw Areas Undergoes Split- Thickness Skin Grafts
Conditions: Keywords:
Split- thickness Skin grafting
Study type:
Interventional
Study phase:
N/A
Overall status:
Recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Prevention
Masking:
None (Open Label)
Intervention:
Intervention type:
Procedure
Intervention name:
Minced skin grafts for donor site
Description:
After harvesting of STSG using watson's knife and coverage of the recipient site, the
excess graft edges will be trimmed and together with any unused graft pieces will be
collected in saline filled plate to prevent graft dissecation. Graft pieces will be
placed over a rigid surface such as dorsum of a stainless steal jar or pot. Mincing of
these small grafts will be done manually using large blade (no. 25) and sharp scissors.
The resulting pasty graft mass composed of a large number of minced skin graft particles
and a small amount of saline solution will be spread onto one half of the donor site
using small dressing forceps.
Minced skin grafts will not be used on the other half (control side). The entire donor
site will be covered with non-adherent absorbable dressing in the form of Vaseline gauze
and sterilized cotton-filled dressing followed by elastic compression bandage.
Arm group label:
Cases
Summary:
Split-thickness skin grafting (STSG) is one of the most commonly performed procedures to
achieve wound closure. Most studies are concerned on improving the appearance of scars
and shortening the healing time of the recipient sites. However, the management of the
donor site usually takes a second consideration.
There is a lack of consensus on the recommended method of donor site management. Donor
site morbidity of STSG is usually minimal, but that may not always be the case. Morbidity
may include pigmentary abnormalities, prolonged pain and itching, delayed healing, or
unfavorable scarring. So, an effort must be taken to find the optimal solution for donor
site healing and minimize morbidity.
Small portions of the skin graft left at the end of the procedure or the graft pieces
obtained after trimming the edges are usually discarded. There have been some studies
demonstrating the benefit of the minced residual skin graft on the donor site, possibly
resulting in earlier epithelialization and improving the appearance
Detailed description:
The aim of this study is to compare the duration of wound healing, scar quality and
cosmetic results of donor sites after split-thickness skin grafting with and without the
use of residual graft pieces as minced skin grafts.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- All patients undergoing split-thickness skin grafting, between 12 - 60 years of age.
Exclusion Criteria:
- Patients under the age of 12 years or above 60 years.
- Patients with a known tendency for hypertrophic scarring/keloids
- Pregnancy
- Co-morbid factors such as uncontrolled diabetes, ischemic heart disease, renal
failure or Collagen vascular disease.
Gender:
All
Minimum age:
12 Years
Maximum age:
60 Years
Healthy volunteers:
Accepts Healthy Volunteers
Locations:
Facility:
Name:
Plastic surgery department, Faculty of medicine, Sohag university
Address:
City:
Sohag
Zip:
02093
Country:
Egypt
Status:
Recruiting
Contact:
Last name:
Mohamed Abd El-Mawla Mohamed, Resident plastic surgeon
Phone:
+0201221953861
Email:
mohamed_abdelmageed@med.sohag.edu.eg
Contact backup:
Last name:
Gamal Yousef Elsayed, Professor of plastic surgery
Phone:
+20 115 6996929
Start date:
December 1, 2023
Completion date:
December 1, 2024
Lead sponsor:
Agency:
Sohag University
Agency class:
Other
Source:
Sohag University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06488612
